Autres langues Akili, Inc.

Actions

AKLI

US00974B1070

Temps réel estimé Cboe BZX Autres places de cotation 16:28:28 12/06/2024			Varia. 5j.	Varia. 1 janv.
0,423 ^USD	+0,74 %		-0,21 %	-13,80 %

14/05	Akili, Inc. communique ses résultats pour le premier trimestre clos le 31 mars 2024	CI
30/04	Akili, Inc. prévoit de continuer à obtenir l'autorisation de mise sur le marché de la Food and Drug Administration des États-Unis pour son produit EndeavorOTC	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 31, 2024, for Shares of Akili, Inc. - AKLI	05/06
AKLI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akili, Inc. Is Fair to Shareholders	03/06
Shareholder Alert: Ademi LLP investigates whether Akili, Inc. has obtained a Fair Price for its Public Shareholders	29/05
PureTech Health's Akili, Virtual Therapeutics Sign Merger Deal to Launch Digital Health Company	29/05
Virtual Therapeutics, Akili Interactive Enter Into Definitive Merger Agreement to Establish Leading Digital Health Company	29/05
Virtual Therapeutics Corp. entered into an agreement to acquire Akili, Inc. for $35 million.	29/05
Akili, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Earnings Flash (AKLI) AKILI Posts Q1 Revenue $383,000, vs. Street Est of $0.8M	14/05
Akili Reports First Quarter 2024 Financial Results and Provides Business Update	14/05
Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results	30/04
Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product	30/04
Akili, Inc. to Reduce Workforce	30/04
Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd	30/04
Akili, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Akili, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Earnings Flash (AKLI) AKILI Posts Q4 Revenue $749,000, vs. Street Est of $0.78M	29/02
Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	29/02
PureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx for Pediatric ADHD Patients in Japan	28/02
Shionogi & Co., Ltd. - Positive Results from Phase 3 Clinical trial of Digital Therapeutic App SDT-001 and Submission for Marketing Approval in Japan	27/02
Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx for Pediatric ADHD Patients in Japan	27/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Akili, Inc.

Actions

AKLI

US00974B1070

Autres langues

Filtres